%PDF-1.4
%
36 0 obj
<>
endobj
33 0 obj
<>
endobj
92 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-05-11T12:55:12Z
2024-03-28T01:50:12-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-28T01:50:12-07:00
application/pdf
Heather
2004-617.june
uuid:bcc0d930-1dd1-11b2-0a00-b80927bd7200
uuid:bcc0d932-1dd1-11b2-0a00-880000000000
endstream
endobj
22 0 obj
<>
endobj
23 0 obj
<>
endobj
37 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 10 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 12 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 14 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 16 0 R/Type/Page>>
endobj
106 0 obj
[110 0 R]
endobj
107 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 61 736.1941 Tm
[(5.)-875.1 (D\325Amico G, Colasanti G, Ferrario F)79.7 (, Sinico RA. Renal involvement)]TJ
1.675 -1.25 Td
(in essential mixed cryoglobulinemia. Kidney Int 1989;35:1004-14.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (Frankel )54.8 (AH, Singer DR, )17.7 (W)39.8 (inearls CG, Evans DJ, Rees )54.8 (AJ, Pusey)]TJ
1.675 -1.25 Td
[(CD. )17.7 (T)69.9 (ype II essential mixed cryoglobulinemia: Presentation,)]TJ
0 -1.25 TD
(treatment and outcome in 13 patients. Q J Med 1992;82:101-24.)Tj
-1.675 -1.25 Td
[(7.)-875.1 (Misiani R, Bellavita P)110.7 (, Fenili D, et al. Interferon alpha-2a therapy)]TJ
1.675 -1.25 Td
(in cryoglobulinemia associated with hepatitis C virus. N Engl J)Tj
0 Tc T*
(Med 1994;330:751-6.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(8.)-875.1 (Ferri C, Marzo E, Longombardo G, et al. Interferon-alpha in mixed)]TJ
1.675 -1.25 Td
[(cryoglobulinemia patients: )54.8 (A)-220.1 (randomized crossover)19.7 (-controlled trial.)]TJ
0 Tc T*
[(Blood 1993;81:1)36.9 (132-6.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(9.)-875.1 (Zuckerman E, Keren D, Slobodin G, et al. )17.7 (T)35 (reatment of refractory)64.9 (,)]TJ
1.675 -1.25 Td
(symptomatic, hepatitis C virus related mixed cryoglobulinemia with)Tj
T*
(ribavirin and interferon-alpha. J Rheumatol 2000;27:2172-8.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (Naarendorp M, Kallemuchikkal U, Nuovo GJ, Gorevic PD.)]TJ
2.175 -1.25 Td
[(Longterm ef)17.7 (ficacy of interferon-alpha for extrahepatic disease)]TJ
T*
(associated with hepatitis C virus infection. J Rheumatol)Tj
0 Tc 0 Tw T*
(2001;28:2466-73.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Cacoub P)110.7 (, Lidove O, Maisonobe )17.7 (T)74 (, et al. Interferon-alpha and)]TJ
2.1381 -1.25 Td
(ribavirin treatment in patients with hepatitis C virus-related)Tj
T*
[(systemic vasculitis. )54.8 (Arthritis Rheum 2002;46:3317-26.)]TJ
-2.175 -1.25 Td
[(12.)-875.1 (Rossi P)110.7 (, Bertani )17.7 (T)74 (, Baio P)110.7 (, et al. Hepatitis C virus-related)]TJ
2.175 -1.25 Td
(cryoglobulinemic glomerulonephritis: long-term remission after)Tj
T*
[(antiviral therapy)64.8 (. Kidney Int 2003;63:2236-41.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (Alric L, Plaisier E, )17.7 (Thebault S, et al. Influence of antiviral therapy)]TJ
2.175 -1.25 Td
[(in hepatitis C virus-associated cryoglobulinemic MPGN. )54.8 (Am J)]TJ
T*
(Kidney Dis 2004;43:617-23.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Dammacco F)79.7 (, Sansonno D, Han JH, et al. Natural interferon-alpha)]TJ
2.175 -1.25 Td
(versus its combination with 6-methyl-prednisolone in the therapy of)Tj
T*
(type II mixed cryoglobulinemia: a long-term, randomized,)Tj
0 Tc T*
[(controlled study)64.9 (. Blood 1994;84:3336-43.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(15.)-875.1 (V)110.8 (assilopoulos D, Calabrese LH. Hepatitis C virus infection and)]TJ
2.175 -1.25 Td
[(vasculitis. )54.8 (Arthritis Rheum 2002;46:585-97.)]TJ
-2.175 -1.25 Td
[(16.)-875.1 (Casato M, )54.8 (Agnello )17.7 (V)128.9 (, Pucillo LP)110.7 (, et al. Predictors of long-term)]TJ
2.175 -1.25 Td
(response to high-dose interferon therapy in type II)Tj
T*
(cryoglobulinemia associated with hepatitis C virus infection. Blood)Tj
0 Tc 0 Tw T*
(1997;90:3865-73.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875.1 (Agnello )17.7 (V)128.9 (.)-0.1 ( )17.7 (Therapy for cryoglobulinemia secondary to hepatitis C)]TJ
2.175 -1.25 Td
(virus: the need for tailored protocols and multiclinic studies. )Tj
T*
(J Rheumatol 2000;27:2065-7.)Tj
-2.175 -1.25 Td
[(18.)-875.1 (Mazzaro C, Franzin F)79.7 (,)-0.1 ( )17.7 (T)35 (ulissi P)110.7 (, et al. Regression of monoclonal B-)]TJ
2.175 -1.25 Td
[(cell expansion in patients af)17.7 (fected by mixed cryoglobulinemia)]TJ
T*
[(responsive to interferon alpha therapy)64.8 (. Cancer 1996;77:2604-13.)]TJ
30.825 52.5 Td
[(19.)-875.1 (Lindsay KL. )17.7 (Therapy of hepatitis C: overview)64.8 (. Hepatology)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(1997;26:71S-77S.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(20.)-875.1 (Lerat H, Hollinger FB. Hepatitis C virus occult infection or occult)]TJ
2.175 -1.25 Td
[(HCV)91.7 (-RNA)-220.2 (detection? J Infect Dis 2004;189:3-6.)]TJ
-2.175 -1.25 Td
[(21.)-875.1 (Musto P)110.7 (. Hepatitis C virus infection and B-cell non-Hodgkin\325)54.8 (s)]TJ
2.175 -1.25 Td
[(lymphomas: more than a simple association. Clin L)54.8 (ymphoma)]TJ
0 Tc 0 Tw T*
(2002;3:150-60.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(22.)-875.1 (De )17.7 (V)59.8 (ita S, Sacco C, Sansonno D, et al. Characterization of overt B-)]TJ
2.175 -1.25 Td
(cell lymphomas in patients with hepatitis C virus infection. Blood)Tj
0 Tc 0 Tw T*
(1997;90:776-82.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(23.)-875.1 (Pozzato G, Mazzaro C, Crovatto M, et al. Low grade malignant)]TJ
2.175 -1.25 Td
(lymphoma, hepatitis C infection and mixed cryoglobulinemia.)Tj
0 Tc T*
(Blood 1994;84:3047-53.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(24.)-875.1 (Monteverde )54.8 (A, Sabattini E, Poggi S, et al. Bone marrow findings)]TJ
2.175 -1.25 Td
(further support the hypothesis that essential mixed)Tj
T*
(cryoglobulinemia type II is characterized by a monoclonal B-cell)Tj
T*
[(proliferation. Leuk L)54.8 (y)-0.1 (mphoma 1995;20:1)36.8 (19-24.)]TJ
-2.175 -1.25 Td
[(25.)-875.1 (Rasul I, Shepherd F)73.9 (A, Kamel-Reid S, Krajden M, Pantalony D,)]TJ
2.175 -1.25 Td
[(Heathcote EJ. Detection of occult low-grade B-cell non-Hodgkin\325)54.8 (s)]TJ
T*
(lymphoma in patients with chronic hepatitis C infection and mixed)Tj
T*
(cryoglobulinemia. Hepatology 1999;29:543-7.)Tj
-2.175 -1.25 Td
[(26.)-875.1 (T)35 (rejo O, Ramos-Casals M, Lopez-Guillermo )54.8 (A, et al. Hematologic)]TJ
2.175 -1.25 Td
(malignancies in patients with cryoglobulinemia: association with)Tj
T*
[(autoimmune and chronic viral diseases. Semin )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2003;33:19-28.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(27.)-875.1 (Dammacco F)79.7 (,)-0.1 ( Sansonno D, Piccoli C, )17.7 (T)35 (ucci F)73.9 (A, Racanelli )17.7 (V)128.9 (.)-0.1 ( )17.7 (The)]TJ
2.175 -1.25 Td
[(cryoglobulins: an overview)64.8 (. Eur J Clin Invest 2001;31:628-38.)]TJ
-2.175 -1.25 Td
[(28.)-875.1 (Hermine O, Lefrere F)79.7 (, Bronowicki JP)110.7 (, et al. Regression of splenic)]TJ
2.175 -1.25 Td
(lymphoma with villous lymphocytes after treatment of hepatitis C)Tj
T*
(virus infection. N Engl J Med 2002;347:89-94.)Tj
-2.175 -1.25 Td
[(29.)-875.1 (Saadoun D, Suarez F)79.7 (, Lefrere F)79.7 (, et al. Splenic lymphoma with)]TJ
2.175 -1.25 Td
(villous lymphocytes, associated with type II cryoglobulinemia and)Tj
T*
[(HCV)-257.3 (infection: a new entity? Blood 2005;105:74-6. )]TJ
-2.175 -1.25 Td
[(30.)-875.1 (De )17.7 (V)59.8 (ita S, De Re )17.7 (V)128.9 (, Gasparotto D, et al. Oligoclonal non-neoplastic)]TJ
2.175 -1.25 Td
(B cell expansion is the key feature of type II mixed)Tj
T*
[(cryoglobulinemia. )54.8 (Arthritis Rheum 2000;43:94-102.)]TJ
-2.175 -1.25 Td
[(31.)-875.1 (Zaja F)79.7 (, De )17.7 (V)59.8 (ita S, Russo D, et al. Rituximab for the treatment of)]TJ
2.175 -1.25 Td
[(type II mixed cryoglobulinemia. )54.8 (Arthritis Rheum 2002;46:2252-4.)]TJ
-2.175 -1.25 Td
[(32.)-875.1 (Sansonno D, De Re )17.7 (V)128.9 (, Lauletta G, )17.7 (T)35 (ucci F)79.7 (, Boiocchi M, Dammacco)]TJ
2.175 -1.25 Td
[(F)79.8 (. Monoclonal antibody treatment of mixed cryoglobulinemia)]TJ
T*
(resistant to interferon alpha with an anti-CD20. Blood)Tj
0 Tc 0 Tw T*
(2003;101:3818-26.)Tj
ET
0 0 0 1 K
53.468 76.5 m
558.468 76.5 l
S
0 0 0 0 k
494.29 69.365 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
8 0 0 8 541.468 56.4344 Tm
(1167)Tj
-0.00011 Tc 0.02499 Tw -60.867 0.0129 Td
(Levine, et al: Cryoglobulinemic vasculitis)Tj
ET
0 0 0 0 k
/GS0 gs
102.631 81.583 407.5 -10.833 re
f*
0.5 w
/GS1 gs
102.631 81.583 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_2 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
16 0 obj
<>stream
8;Z\7$[0B@%+G/.R-P/o/BMUh(+?i//Rjd,20&PVALM-K0*/lUm<5IQf`$#Ch>d9/
EPJWTl\>ZP8i$)?:Utg:&4X*Ck'>-E*b3GU
%n5=&\>9Z6Y*F!2.i?eVq?CgN2o(1rbBPTm5F@rH)An[m4a[K8M)'.n(UQqhd`J,9!]h
ZjRI^8QO:7:mC`CSQ#?2$V[I'gG,-R:lNoCesuFih"E_I37Y4Ma0*lB5ppB@[?_"M
Z<+7mYQ\X\HP`onZDB-d@,`VR0N[!,qY(/6*dl8BF,ks2%rTXiQ$NZGt:74Sr2*IMa
gQT=eba\QNAnf+6P8i24EbIbkUGe$%*K*mr*HS`*\
G)?+0V9BWHD<@>-38d#A@bJhVk,loUF!$+H4J#G]F,IG:am.q)bAkPO@)i&'`?dW^
1uP%R*IBI@I!58$_SX1,_SX0."^]!kb0.hTatNW`48RnnFmf'U(B+Pf"orgF>sA~>
endstream
endobj
20 0 obj
[/Indexed/DeviceRGB 255 19 0 R]
endobj
19 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
49 0 obj
<>
endobj
43 0 obj
<>
endobj
83 0 obj
<>
endobj
97 0 obj
<>
endobj
42 0 obj
<>
endobj
77 0 obj
<>stream
HtTkPWf1ͣ(V*F7"PD|B4:Ay8h4 "2;">"j`,**nbW6NU!ڭ[uֽsw1k+)a͎P%*>+S żq~ϊxkvd{+wFKPb5~bhwۓܙ`)FMeCc]Y1<bJm2Q+_$5Te\< !A>~V*5iċ*\!O(b
M\'_JRf$+!rER